Guardant Health (Guardant Health) Forward Dividend Yield % : 0.00% (As of May. 16, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Guardant Health Forward Dividend Yield %?

As of today (2024-05-16), the Forward Annual Dividend Yield of Guardant Health is 0.00%.

As of today (2024-05-16), the Trailing Annual Dividend Yield of Guardant Health is 0.00%.

GH's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.88
* Ranked among companies with meaningful Forward Dividend Yield % only.

Guardant Health's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Guardant Health's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Guardant Health's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Guardant Health's Forward Dividend Yield % falls into.

Guardant Health Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Guardant Health (NAS:GH) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Guardant Health Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Guardant Health's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (Guardant Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Executives

Meghan V. Joyce	director	THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia	officer: Chief Information Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber	officer: Chief Operating Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova	officer: Chief Technology Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy	director, officer: Chief Executive Officer	2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz	director, officer: Chairman, President and COO	18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq	director	3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill	officer: SVP, People	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman	director	2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman	officer: Chief Commercial Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde	director	C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103